[Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections]

Author(s): Liu Y, Wang R, Yu B

Affiliation(s): Department of Respiratory Diseases, Chinese PLA General Hospital, Beijing 100853, China.

Publication date & source: 2001-01-10, Zhonghua Yi Xue Za Zhi., 81(1):41-4.

Publication type: Clinical Trial; Multicenter Study; Randomized Controlled Trial

OBJECTIVE: To compare the efficacy and safety of domestic piperacillin/tazobactam with those of Timentin in treatment of acute bacterial infections. METHOD: A randomized controlled multicentre trial and an opening clinical trial were conducted in 4 hospitals in Beijing. RESULT: The cure and efficacy rates in the test group were 73.0% (46/63) and 96.8% (61/63), respectively and the bacterial clearance rate was 91.7% (55/60). The cure and efficacy rates in the control group were 58.7% (37/63) and 97.7% (43/44) respectively, and the bacterial clearance rate was 87.9% (51/58). The difference between the two groups was not statistically significant. The cure rate, efficacy rate and bacterial clearance rate in the opening group were 72.7% (32/44), 97.7% (43/44) and 88.4% (38/43) respectively. No serious adverse drug reaction was found during the treatment with piperacillin/tazobactam. CONCLUSION: Domestic piperacillin/tazobactam is effective and safe for the treatment of acute bacterial infections.